BioDelivery Sciences to Report First Quarter 2019 Financial Results

RALEIGH, N.C., April 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that it will report its first quarter 2019 financial results after the close of the U.S. financial markets on Monday, May 6, 2019. The company will host a conference call at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial In & Webcast Information:

About BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, and opioid dependence. For more information, please visit us at www.bdsi.com or follow us on Facebook.com/BioDeliverySI or Twitter BDSI @BioDeliverySI.

Mary Coleman 
919-582-0188
[email protected]

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• Colony Bankcorp to acquire First Reliance in $163M stock-and-cash deal
• Currenc Group suspends Indonesian WalletKu unit operations